These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 26998905

  • 1. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B.
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [Abstract] [Full Text] [Related]

  • 3. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
    Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Uitdehaag BM, Barkhof F, Killestein J, Wattjes MP.
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [Abstract] [Full Text] [Related]

  • 5. Long-term effectiveness and safety of natalizumab in a Portuguese population.
    Correia I, Batista S, Galego O, Marques IB, Jesus-Ribeiro J, Martins AI, Nunes C, Macário MC, Cunha L, Sousa L.
    Int Immunopharmacol; 2017 May; 46():105-111. PubMed ID: 28282574
    [Abstract] [Full Text] [Related]

  • 6. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L, Vijiaratnam N, Skibina O.
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [Abstract] [Full Text] [Related]

  • 7. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
    Martí G, Río J, Rovira À, Auger C, Tintoré M, Sastre-Garriga J, Vidal A, Castilló J, Montalban X.
    Rev Neurol; 2015 Feb 16; 60(4):164-8. PubMed ID: 25670046
    [Abstract] [Full Text] [Related]

  • 8. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb 16; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 9. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy.
    Budhram A, Pelikan JB, Kremenchutzky M, Sharma M.
    J Neurol Sci; 2017 Apr 15; 375():304-306. PubMed ID: 28320156
    [No Abstract] [Full Text] [Related]

  • 10. CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study.
    Häusler D, Akgün K, Stork L, Lassmann H, Ziemssen T, Brück W, Metz I.
    Brain Pathol; 2021 Nov 15; 31(6):e12969. PubMed ID: 33955606
    [Abstract] [Full Text] [Related]

  • 11. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    Schneider R, Bellenberg B, Hoepner R, Kolb EM, Ellrichmann G, Haghikia A, Gold R, Lukas C.
    PLoS One; 2017 Nov 15; 12(4):e0176415. PubMed ID: 28445498
    [Abstract] [Full Text] [Related]

  • 12. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 13. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
    Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Moral E, Meca J, Montalbán X.
    Neurologia; 2015 Jun 12; 30(5):302-14. PubMed ID: 24360652
    [Abstract] [Full Text] [Related]

  • 14. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.
    Pediatr Neurol; 2017 May 12; 70():56-60. PubMed ID: 28389054
    [Abstract] [Full Text] [Related]

  • 15. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.
    Eur J Neurol; 2016 Jun 12; 23(6):1079-85. PubMed ID: 27018481
    [Abstract] [Full Text] [Related]

  • 16. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Hodel J, Darchis C, Outteryck O, Verclytte S, Deramecourt V, Lacour A, Zins M, Pruvo JP, Vermersch P, Leclerc X.
    Neurology; 2016 Apr 19; 86(16):1516-23. PubMed ID: 27009257
    [Abstract] [Full Text] [Related]

  • 17. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
    Kolcava J, Hulova M, Benesova Y, Bednarik J, Stourac P.
    Mult Scler Relat Disord; 2019 May 19; 30():187-191. PubMed ID: 30785075
    [Abstract] [Full Text] [Related]

  • 18. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB.
    J Neurovirol; 2015 Dec 19; 21(6):637-44. PubMed ID: 25771865
    [Abstract] [Full Text] [Related]

  • 19. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar 19; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 20. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P, Rocca MA, Pagani E, Storelli L, Rodegher M, Moiola L, Filippi M.
    J Neurol Neurosurg Psychiatry; 2020 May 19; 91(5):493-502. PubMed ID: 32111638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.